Cited by 874HER2/EGFR in Cancer ResearchLung Cancer Treatments and MutationsPI3K/AKT/mTOR signaling in cancer

The DOI matches its Crossref record; 73 of the 83 references it cites were found in a registry or an index.

Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth

Open access

Agus, David B, Akita, Robert W, Fox, William D, Lewis, Gail D, Higgins, Brian, Pisacane, Paul I, Lofgren, Julie A, Tindell, Charles, Evans, Douglas P, Maiese, Krista, Scher, Howard I, Sliwkowski, Mark X·2002·Cancer Cell

DOI 10.1016/s1535-6108(02)00097-1

Open this paper in CoChat — free account Open PDF

Abstract

ErbB2 is a ligand-less member of the ErbB receptor family that functions as a coreceptor with EGFR, ErbB3, and ErbB4. Here, we describe an approach to target ErbB2's role as a coreceptor using a monoclonal antibody, 2C4, which sterically hinders ErbB2's recruitment into ErbB ligand complexes. Inhibition of ligand-dependent ErbB2 signaling by 2C4 occurs in both low- and high-ErbB2-expressing systems. Since the ErbB3 receptor contains an inactive tyrosine kinase domain, 2C4 is very effective in blocking heregulin-mediated ErbB3-ErbB2 signaling. We demonstrate that the in vitro and in vivo growth of several breast and prostate tumor models is inhibited by 2C4 treatment.

Integrity signals

Registry

Crossref · 10.1016/s1535-6108(02)00097-1

Cites

73 of 73 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/ neu Oncogene
Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., & McGuire, W. L. (1987) · Science · doi:10.1126/science.3798106 · Cited by 11,760
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500
Untangling the ErbB signalling network
Yarden, Y., & Sliwkowski, M. X. (2001) · Nature Reviews Molecular Cell Biology · doi:10.1038/35052073 · Cited by 6,974
Self-citation
Real time quantitative PCR.Preprint
Heid, C., Stevens, J., Livak, K. J., & Williams, P. (1996) · Genome Research · doi:10.1101/gr.6.10.986 · Cited by 6,180
Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets
Clynes, R. A., Towers, T. L., Presta, L. G., & Ravetch, J. V. (2000) · Nature Medicine · doi:10.1038/74704 · Cited by 2,768
Multinational Study of the Efficacy and Safety of Humanized Anti-HER2 Monoclonal Antibody in Women Who Have HER2-Overexpressing Metastatic Breast Cancer That Has Progressed After Chemotherapy for Metastatic Disease
Cobleigh, M., Vogel, C. L., Tripathy, D., Robert, N. J., Scholl, S., Fehrenbacher, L., Wolter, J. M., Paton, V. E., Shak, S., Lieberman, G., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.9.2639 · Cited by 2,767
A novel method for real time quantitative RT-PCR.Preprint
Gibson, U. E., Heid, C., & Williams, P. M. (1996) · Genome Research · doi:10.1101/gr.6.10.995 · Cited by 2,090
ErbB‐2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling
Graus-Porta, D., Beerli, R. R., Daly, J. M., & Hynes, N. E. (1997) · The EMBO Journal · doi:10.1093/emboj/16.7.1647 · Cited by 1,617
The EGF receptor family as targets for cancer therapy
Mendelsohn, J. M., & Baselga, J. M. (2000) · Oncogene · doi:10.1038/sj.onc.1204082 · Cited by 1,341
Phase I and Pharmacologic Study of OSI-774, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Advanced Solid Malignancies
Hidalgo, M., Siu, L. L., Nemunaitis, J., Rizzo, J., Hammond, L. A., Takimoto, C., Eckhardt, S. G., Tolcher, A., Britten, C. D., Denis, L., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.13.3267 · Cited by 1,001

Show all 83 references

Research works printed but not linked: 6

Agus, 1999, Prostate cancer cell cycle regulators, J. Natl. Cancer Inst., 91, 1869, 10.1093/jnci/91.21.1869 · DOI
Lewis, 1996, Growth regulation of human breast and ovarian tumor cells by heregulin, Cancer Res., 56, 1457
Nagabhushan, 1996, CWR22, Cancer Res., 56, 3042
Pinkas-Kramarski, 1996, Diversification of Neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions, EMBO J., 15, 2452, 10.1002/j.1460-2075.1996.tb00603.x · DOI
Tzahar, 1998, The ErbB-2/HER2 oncogenic receptor of adenocarcinomas, Biochim. Biophys. Acta, 1377, M25
Wainstein, 1994, CWR22, Cancer Res., 54, 6049

Sorted by citations

Items 101–200 of 874

Management of breast cancer with targeted agents: importance of heterogenicity
Cosimo, S. D., & Baselga, J. M. (2010) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2009.234 · Cited by 159
Clinical development of immunotherapies for HER2+ breast cancer: a review of HER2-directed monoclonal antibodies and beyond
Costa, R. L. B., & Czerniecki, B. J. (2020) · npj Breast Cancer · doi:10.1038/s41523-020-0153-3 · Cited by 169
Cardiac Toxicity and Efficacy of Trastuzumab Combined with Pertuzumab in Patients with Trastuzumab-Insensitive Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer
Portera, C. C., Walshe, J. M., Rosing, D. R., Denduluri, N., Berman, A. W., Vatas, U., Velarde, M., Chow, C. K., Steinberg, S. M., Nguyen, D., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4636 · Cited by 156
Activation of ErbB3, EGFR and Erk is essential for growth of human breast cancer cell lines with acquired resistance to fulvestrant
Frogne, T., Benjaminsen, R. V., Sonne‐Hansen, K., Sørensen, B. S., Nexø, E., Lænkholm, A., Rasmussen, L. M., Riese, D. J., de Crémoux, P., Stenvang, J., et al. (2008) · Breast Cancer Research and Treatment · doi:10.1007/s10549-008-0011-8 · Cited by 157
Targeted therapies in gynecological cancers: a comprehensive review of clinical evidence
Wang, Q., Peng, H., Qi, X., Wu, M., & Zhao, X. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-0199-6 · Cited by 162
Renaissance of cancer therapeutic antibodies
Glennie, M. J., & van de Winkel, J. G. J. (2003) · Drug Discovery Today · doi:10.1016/s1359-6446(03)02714-4 · Cited by 155
HER3 and downstream pathways are involved in colonization of brain metastases from breast cancer
Silva, L. M. D., Simpson, P. T., Smart, C. E., Cocciardi, S., Waddell, N., Lane, A., Morrison, B. J., Vargas, A. C., Healey, S. C., Beesley, J., et al. (2010) · Breast Cancer Research · doi:10.1186/bcr2603 · Cited by 155
Dual inhibition of ErbB1 (EGFR/HER1) and ErbB2 (HER2/neu)
Reid, A. H. M., Vidal, L., Shaw, H. M., & Bono, J. S. D. (2007) · European Journal of Cancer · doi:10.1016/j.ejca.2006.11.007 · Cited by 155
The HER family and cancer: emerging molecular mechanisms and therapeutic targets
Sergina, N. V., & Moasser, M. M. (2007) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2007.10.002 · Cited by 172
A Critical Role for HSP90 in Cancer Cell Invasion Involves Interaction with the Extracellular Domain of HER-2
Sidera, K., Gaitanou, M., Stellas, D., Matsas, R., & Patsavoudi, E. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m701803200 · Cited by 154
Clinical benefit of lapatinib-based therapy in patients with human epidermal growth factor receptor 2-positive breast tumors coexpressing the truncated p95HER2 receptor
Scaltriti, M., Chandarlapaty, S., Prudkin, L., Aura, C., Jimenez, J., Angelini, P. D., Sánchez, G., Guzman, M., Parra, J. L., Ellis, C., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-3407 · Cited by 151
Overcoming implementation challenges of personalized cancer therapy
Meric‐Bernstam, F., & Mills, G. B. (2012) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2012.127 · Cited by 150
The insulin and EGF receptor structures: new insights into ligand-induced receptor activation
Ward, C. W., Lawrence, M. C., Streltsov, V. A., Adams, T. E., & McKern, N. M. (2007) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2007.01.001 · Cited by 148
Potent anti-proliferative effects of metformin on trastuzumab-resistant breast cancer cells via inhibition of erbB2/IGF-1 receptor interactions
Liu, B., Fan, Z., Edgerton, S. M., Yang, X., Lind, S. E., & Thor, A. D. (2011) · Cell Cycle · doi:10.4161/cc.10.17.16359 · Cited by 120
Treatment of HER2-overexpressing breast cancer
Baselga, J. M. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq421 · Cited by 146
Epidermal Growth Factor Receptor Family and its Role in Gastric Cancer
Arienti, C., Pignatta, S., & Tesei, A. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.01308 · Cited by 145
Targeting EGFR and HER-2 receptor tyrosine kinases for cancer drug discovery and development
Kamath, S., & Buolamwini, J. K. (2006) · Medicinal Research Reviews · doi:10.1002/med.20070 · Cited by 145
Mechanisms of resistance to HER family targeting antibodies
Kruser, T. J., & Wheeler, D. L. (2010) · Experimental Cell Research · doi:10.1016/j.yexcr.2010.01.009 · Cited by 142
Heregulin-Induced Activation of HER2 and HER3 Increases Androgen Receptor Transactivation and CWR-R1 Human Recurrent Prostate Cancer Cell Growth
Gregory, C. W., Whang, Y. E., McCall, W., Fei, X., Liu, Y., Ponguta, L. A., French, F. S., Wilson, E. M., & Earp, H. S. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-1158 · Cited by 140
The Evolving Landscape of HER2 Targeting in Breast Cancer
Moasser, M. M., & Krop, I. E. (2015) · JAMA Oncology · doi:10.1001/jamaoncol.2015.2286 · Cited by 135
Development of Herceptin resistance in breast cancer cells
Kute, T. E., Läck, C. M., Willingham, M. C., Bishwokama, B., Williams, H. C., Barrett, K., Mitchell, T., & Vaughn, J. P. (2003) · Cytometry Part A · doi:10.1002/cyto.a.10095 · Cited by 136
Effective Suppression of Vascular Network Formation by Combination of Antibodies Blocking VEGFR Ligand Binding and Receptor Dimerization
Tvorogov, D., Anisimov, A., Zheng, W., Leppänen, V., Tammela, T., Laurinavičius, S., Holnthoner, W., Heloterä, H., Holopainen, T., Jeltsch, M., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.11.001 · Cited by 135
Open-Label Phase II Study Evaluating the Efficacy and Safety of Two Doses of Pertuzumab in Castrate Chemotherapy-Naive Patients With Hormone-Refractory Prostate Cancer
Bono, J. S. D., Joaquim Bellmunt, B., Attard, G., Droz, J. P., Miller, K., Fléchon, A., Sternberg, C. N., Parker, C. C., Zugmaier, G., Hersberger-Gimenez, V., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.0888 · Cited by 137
HER2 Phosphorylation Is Maintained by a PKB Negative Feedback Loop in Response to Anti-HER2 Herceptin in Breast Cancer
Gijsen, M., King, P., Perera, T., Parker, P. J., Harris, A. L., Larijani, B., & Kong, A. H. (2010) · PLoS Biology · doi:10.1371/journal.pbio.1000563 · Cited by 129
Targeting Angiogenesis With Integrative Cancer Therapies
Yance, D. R., & Sagar, S. M. (2006) · Integrative Cancer Therapies · doi:10.1177/1534735405285562 · Cited by 129
Advances in Targeting Human Epidermal Growth Factor Receptor-2 Signaling for Cancer Therapy
Meric‐Bernstam, F., & Hung, M. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1732 · Cited by 129
Identification and validation of cell surface antigens for antibody targeting in oncology
Carter, P. M., Smith, L. M., & Ryan, M. C. (2004) · Endocrine Related Cancer · doi:10.1677/erc.1.00766 · Cited by 130
Advances in Novel Drug Delivery Strategies for Breast Cancer Therapy
Dhankhar, R., Vyas, S. P., Jain, A., Arora, S., Rath, G., & Goyal, A. K. (2010) · Artificial Cells Blood Substitutes and Biotechnology · doi:10.3109/10731199.2010.494578 · Cited by 128
Targeting ErbB2 and ErbB3 with a bispecific single-chain Fv enhances targeting selectivity and induces a therapeutic effect in vitro
Robinson, M. K., Hodge, K. M., Horak, E. M., Sundberg, Å. L., Russeva, M., Shaller, C. C., von Mehren, M., Shchaveleva, I., Simmons, H. H., Marks, J. D., et al. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604700 · Cited by 131
Dysregulation of cellular signaling by HER2 in breast cancer
Zhou, B. P. (2003) · Seminars in Oncology · doi:10.1053/j.seminoncol.2003.08.006 · Cited by 127
The role of HER2 in early breast cancer metastasis and the origins of resistance to HER2-targeted therapies
Freudenberg, J. A., Wang, Q., Katsumata, M., Drebin, J. A., Nagatomo, I., & Greene, M. I. (2009) · Experimental and Molecular Pathology · doi:10.1016/j.yexmp.2009.05.001 · Cited by 135
Antibody Fragments as Potential Biopharmaceuticals for Cancer Therapy: Success and Limitations
Kholodenko, R. V., Kalinovsky, D. V., Doronin, I. I., Ponomarev, E. D., & Kholodenko, I. V. (2019) · Current Medicinal Chemistry · doi:10.2174/0929867324666170817152554 · Cited by 125
Biological impediments to monoclonal antibody–based cancer immunotherapy
Christiansen, J., & Rajasekaran, A. K. (2004) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.1493.3.11 · Cited by 125
Estrogen receptor-positive breast cancer molecular signatures and therapeutic potentials (Review)
ZHANG, M. H., Man, H., Zhao, X., DONG, N., & Shi, L. (2013) · Biomedical Reports · doi:10.3892/br.2013.187 · Cited by 138
Suppression of HER2/HER3-Mediated Growth of Breast Cancer Cells with Combinations of GDC-0941 PI3K Inhibitor, Trastuzumab, and Pertuzumab
Yao, E. S., Zhou, W., Lee-Hoeflich, S. T., Truong, T., Haverty, P. M., Eastham‐Anderson, J., Lewin‐Koh, N., Gunter, B., Belvin, M. P., Murray, L. J., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2814 · Cited by 125
Self-citation
Understanding the biology of HER3 receptor as a therapeutic target in human cancer
Lyu, H., Han, A., Polsdofer, E., Liu, S., & Liu, B. (2018) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2018.05.010 · Cited by 125
Biomarker analysis of the NeoSphere study: pertuzumab, trastuzumab, and docetaxel versus trastuzumab plus docetaxel, pertuzumab plus trastuzumab, or pertuzumab plus docetaxel for the neoadjuvant treatment of HER2-positive breast cancer
Bianchini, G., Kiermaier, A. C., Bianchi, G., Im, Y., Pieńkowski, T., Liu, M.-C., Tseng, L., Dowsett, M., Zabaglo, L. A., Kirk, S., et al. (2017) · Breast Cancer Research · doi:10.1186/s13058-017-0806-9 · Cited by 124
HER2 Dimerization Inhibitor Pertuzumab - Mode of Action and Clinical Data in Breast Cancer
Harbeck, N., Beckmann, M. W., Rody, A., Schneeweiß, A., Müller, V., Fehm, T. N., Marschner, N. W., Gluz, O., Schrader, I., Heinrich, G., et al. (2013) · Breast Care · doi:10.1159/000346837 · Cited by 123
An Antibody That Locks HER3 in the Inactive Conformation Inhibits Tumor Growth Driven by HER2 or Neuregulin
Garner, A. P., Bialucha, C. U., Sprague, E. R., Garrett, J. T., Sheng, Q., Li, S., Sineshchekova, O., Saxena, P., Sutton, C. R., Chen, D., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-1198 · Cited by 125
Current State and Future Challenges for PI3K Inhibitors in Cancer Therapy
Sirico, M., D’Angelo, A., Gianni, C., Casadei, C., Merloni, F., & De Giorgi, U. (2023) · Cancers · doi:10.3390/cancers15030703 · Cited by 121
Pooled analysis of cardiac safety in patients with cancer treated with pertuzumab
Lenihan, D. J., Suter, T. M., Brammer, M. G., Neate, C., Ross, G. A., & Baselga, J. M. (2011) · Annals of Oncology · doi:10.1093/annonc/mdr294 · Cited by 120
Correction: HER2 Phosphorylation Is Maintained by a PKB Negative Feedback Loop in Response to Anti-HER2 Herceptin in Breast Cancer
Gijsen, M., King, P., Perera, T., Parker, P. J., Harris, A. L., Larijani, B., & Kong, A. H. (2016) · PLoS Biology · doi:10.1371/journal.pbio.1002414 · Cited by 120
Recent advances of therapeutic targets based on the molecular signature in breast cancer: genetic mutations and implications for current treatment paradigms
Lima, Z. S., Ghadamzadeh, M., Arashloo, F. T., Amjad, G., Ebadi, M. R., & Younesi, L. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0725-6 · Cited by 123
Signal transduction in prostate cancer progression
Gioeli, D. G. (2005) · Clinical Science · doi:10.1042/cs20040329 · Cited by 117
G Proteins in Cancer: The Prostate Cancer Paradigm
Daaka, Y. (2004) · Science s STKE · doi:10.1126/stke.2162004re2 · Cited by 117
In vitro activity of pertuzumab in combination with trastuzumab in uterine serous papillary adenocarcinoma
ElSahwi, K. S., Bellone, S., Cocco, E., Cargnelutti, M., Casagrande, F., Bellone, M., Abu-Khalaf, M., Buza, N., Tavassoli, F. A., Hui, P., et al. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6605448 · Cited by 116
Novel therapeutic strategies targeting the epidermal growth factor receptor (EGFR) family and its downstream effectors in breast cancer
Atalay, G., Cardoso, F., Awada, A. H., & Piccart, M. J. (2003) · Annals of Oncology · doi:10.1093/annonc/mdg365 · Cited by 116
Expanding the Boundaries of Biotherapeutics with Bispecific Antibodies
Husain, B., & Ellerman, D. A. (2018) · BioDrugs · doi:10.1007/s40259-018-0299-9 · Cited by 116
Growth Factor Receptors in Breast Cancer: Potential for Therapeutic Intervention
Nahta, R., Hortobágyi, G. N., & Esteva, F. J. (2003) · The Oncologist · doi:10.1634/theoncologist.8-1-5 · Cited by 116
Mechanisms of resistance to anti‐human epidermal growth factor receptor 2 agents in breast cancer
Mukohara, T. (2010) · Cancer Science · doi:10.1111/j.1349-7006.2010.01711.x · Cited by 113
Selection and Characterization of Her2 Binding-designed Ankyrin Repeat Proteins
Zahnd, C., Pecorari, F., Straumann, N., Wyler, E., & Plückthun, A. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m602547200 · Cited by 114
Evolving novel anti-HER2 strategies
Jones, K. L., & Buzdar, A. U. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70315-8 · Cited by 112
Neuregulins and Cancer
Montero, J. C., Barrueco, R. R., Ocaña, A., Dı́az-Rodrı́guez, E., Esparı́s-Ogando, A., & Pandiella, A. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-5133 · Cited by 111
The brain microenvironment mediates resistance in luminal breast cancer to PI3K inhibition through HER3 activation
Kodack, D. P., Askoxylakis, V., Ferraro, G. B., Sheng, Q., Badeaux, M. D., Goel, S., Qi, X., Shankaraiah, R. C., Cao, Z. A., Ramjiawan, R. R., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aal4682 · Cited by 110
ERBB3 mutations in cancer: biological aspects, prevalence and therapeutics
Kiavué, N., Cabel, L., Melaabi, S., Bataillon, G., Callens, C., Lerebours, F., Pierga, J., & Bidard, F. (2019) · Oncogene · doi:10.1038/s41388-019-1001-5 · Cited by 109
Integration of rapid signaling events with steroid hormone receptor action in breast and prostate cancer.
Lange, C., Gioeli, D., Hammes, S., & Marker, P. C. (2007) · Annual Review of Physiology · doi:10.1146/annurev.physiol.69.031905.160319 · Cited by 122
The HER receptor family: a rich target for therapeutic development
MASS, R. D. (2004) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2003.09.093 · Cited by 108
Efficacy and Safety of Single-Agent Pertuzumab (rhuMAb 2C4), a Human Epidermal Growth Factor Receptor Dimerization Inhibitor, in Castration-Resistant Prostate Cancer After Progression From Taxane-Based Therapy
Agus, D. B., Sweeney, C. J., Morris, M. J., Mendelson, D. S., McNeel, D. G., Ahmann, F. R., Wang, J., Derynck, M. K., Ng, K., Lyons, B., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.0649 · Cited by 107
Self-citation
Mechanisms of tumor resistance to EGFR-targeted therapies
Hopper-Borge, E. A., Nasto, R. E., Ratushny, V., Weiner, L. M., Golemis, E. A., & Astsaturov, I. A. (2009) · Expert Opinion on Therapeutic Targets · doi:10.1517/14712590902735795 · Cited by 109
Co-Occurring Gain-of-Function Mutations in HER2 and HER3 Modulate HER2/HER3 Activation, Breast Cancer Progression, and HER2 Inhibitor Sensitivity
Hanker, A. B., Brown, B. P., Meiler, J., Marín, A., Jayanthan, H. S., Ye, D., Lin, C.-C. A., Akamatsu, H., Lee, K., Chatterjee, S., et al. (2020) · Cancer Cell · doi:10.1016/j.ccell.2021.06.001 · Cited by 104
Toward a magic or imaginary bullet? Ligands for drug targeting to cancer cells: principles, hopes, and challenges
Sikorski, A. F., Toporkiewicz, M., Meissner, J. M., Matusewicz, L., & Czogalla, A. (2015) · International Journal of Nanomedicine · doi:10.2147/ijn.s74514 · Cited by 104
Blockade of Epidermal Growth Factor- or Heregulin-Dependent ErbB2 Activation with the Anti-ErbB2 Monoclonal Antibody 2C4 Has Divergent Downstream Signaling and Growth Effects
Jackson, J. G., Clair, P. S., Sliwkowski, M. X., & Brattain, M. G. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3106 · Cited by 104
Self-citation
First-in-Human, Phase 1 Dose-Escalation Study of Biparatopic Anti-HER2 Antibody–Drug Conjugate MEDI4276 in Patients with HER2-positive Advanced Breast or Gastric Cancer
Pegram, M. D., Hamilton, E. P., Tan, A. R., Storniolo, A. M., Balic, K., Rosenbaum, A. I., Liang, M., He, P., Marshall, S. A., Scheuber, A., et al. (2021) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-20-0014 · Cited by 105
Efficacy and Safety of Single-Agent Pertuzumab, a Human Epidermal Receptor Dimerization Inhibitor, in Patients with Non–Small Cell Lung Cancer
Herbst, R. S., Davies, A. M., Natale, R. B., Dang, T. P., Schiller, J. H., Garland, L. L., Miller, V. A., Mendelson, D. S., den Abbeele, A. D. V., Melenevsky, Y. V., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0460 · Cited by 101
Inhibition of HER-2/neu Kinase Impairs Androgen Receptor Recruitment to the Androgen Responsive Enhancer
Liu, Y., Majumder, S., McCall, W., Sartor, C. I., Mohler, J. L., Gregory, C. W., Earp, H. S., & Whang, Y. E. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-4292 · Cited by 99
Dual Blockade of HER2 in HER2-Overexpressing Tumor Cells Does Not Completely Eliminate HER3 Function
Garrett, J. T., Sutton, C. R., Kuba, M. G., Cook, R. S., & Arteaga, C. L. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2024 · Cited by 99
Challenges and opportunities in metastatic breast cancer treatments: Nano-drug combinations delivered preferentially to metastatic cells may enhance therapeutic response
Yu, J., Mu, Q., Fung, M., Xu, X., Zhu, L., & Ho, R. J. Y. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108108 · Cited by 103
Rationale for Fixed Dosing of Pertuzumab in Cancer Patients Based on Population Pharmacokinetic Analysis
Ng, C. M., Lum, B. L., Giménez, V. C., Kelsey, S. M., & Allison, D. (2006) · Pharmaceutical Research · doi:10.1007/s11095-006-0205-x · Cited by 99
Macrophage-Mediated Trogocytosis Leads to Death of Antibody-Opsonized Tumor Cells
Velmurugan, R., Challa, D. K., Ram, S., Ober, R. J., & Ward, E. S. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0335 · Cited by 99
Pertuzumab, a novel HER dimerization inhibitor, inhibits the growth of human lung cancer cells mediated by the HER3 signaling pathway
Sakai, K., Yokote, H., Murakami‐Murofushi, K., Tamura, T., Saijo, N., & Nishio, K. (2007) · Cancer Science · doi:10.1111/j.1349-7006.2007.00553.x · Cited by 96
Breast Cancer in the Personal Genomics Era
Ellsworth, R. E., Decewicz, D. J., Shriver, C. D., & Ellsworth, D. L. (2010) · Current Genomics · doi:10.2174/138920210791110951 · Cited by 97
Combination Treatment with Erlotinib and Pertuzumab against Human Tumor Xenografts Is Superior to Monotherapy
Friess, T., Scheuer, W., & Hasmann, M. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2642 · Cited by 95
Targeting ErbB receptor signaling: A pan-ErbB approach to cancer
Britten, C. D. (2004) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.1335.3.10 · Cited by 95
Preclinical studies with Erlotinib (Tarceva)
Akita, R. W., & Sliwkowski, M. X. (2003) · Seminars in Oncology · doi:10.1016/s0093-7754(03)70011-6 · Cited by 95
Self-citation
A phase IIa dose-finding and safety study of first-line pertuzumab in combination with trastuzumab, capecitabine and cisplatin in patients with HER2-positive advanced gastric cancer
Kang, Y.-K., Rha, S. Y., Tassone, P., Barriuso, J., Yu, R., Szado, T., Garg, A., & Bang, Y.-J. (2014) · British Journal of Cancer · doi:10.1038/bjc.2014.356 · Cited by 94
Pertuzumab in the treatment of HER2-positive breast cancer: an evidence-based review of its safety, efficacy, and place in therapy
Ishii, K., Morii, N., & Yamashiro, H. (2019) · Core evidence · doi:10.2147/ce.s217848 · Cited by 95
Molecular Pathways: Targeting NRG1 Fusions in Lung Cancer
Fernandez‐Cuesta, L., & Thomas, R. K. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0854 · Cited by 95
Racial Disparity of Epidermal Growth Factor Receptor Expression in Prostate Cancer
Shuch, B. M., Mikhail, M., Satagopan, J. M., Lee, P., Yee, H. T., Chang, C. A., Cordon‐Cardo, C., Taneja, S. S., & Osman, I. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.06.134 · Cited by 92
Interaction of antibodies with ErbB receptor extracellular regions
Schmitz, K. R., & Ferguson, K. M. (2008) · Experimental Cell Research · doi:10.1016/j.yexcr.2008.10.008 · Cited by 91
Beyond trastuzumab: novel therapeutic strategies in HER2-positive metastatic breast cancer
Tsang, R. Y., & Finn, R. S. (2012) · British Journal of Cancer · doi:10.1038/bjc.2011.516 · Cited by 90
Strategies to target HER2/neu overexpression for cancer therapy
Chen, J., Lan, K., & Hung, M. (2003) · Drug Resistance Updates · doi:10.1016/s1368-7646(03)00040-2 · Cited by 90
Activating Mutations in ERBB2 and Their Impact on Diagnostics and Treatment
Herter-Sprie, G. S., Greulich, H. E., & Wong, K. (2013) · Frontiers in Oncology · doi:10.3389/fonc.2013.00086 · Cited by 88
Fifty years of monoclonals: the past, present and future of antibody therapeutics
Chan, A. C., Martyn, G. D., & Carter, P. J. (2025) · Nature reviews. Immunology · doi:10.1038/s41577-025-01207-9 · Cited by 104
Immuno-gene therapy of established prostate tumors using chimeric receptor-redirected human lymphocytes.
Pinthus, J. H., Waks, T., Kaufman‐Francis, K., Schindler, D. G., Harmelin, A., Kanety, H., Ramon, J., & Eshhar, Z. (2003) · PubMed · Cited by 89
Molecular Mechanisms of Trastuzumab-Based Treatment in HER2-Overexpressing Breast Cancer
Nahta, R. (2012) · ISRN Oncology · doi:10.5402/2012/428062 · Cited by 93
Primary and acquired resistance to EGFR-targeted therapies in colorectal cancer: impact on future treatment strategies
Leto, S. M., & Trusolino, L. (2014) · Journal of Molecular Medicine · doi:10.1007/s00109-014-1161-2 · Cited by 87
Targeted therapies in breast cancer: Where are we now?
Cosimo, S. D., & Baselga, J. M. (2008) · European Journal of Cancer · doi:10.1016/j.ejca.2008.09.026 · Cited by 89
β4 Integrin signaling induces expansion of prostate tumor progenitors
Yoshioka, T., Otero, J. A., Chen, Y., Kim, Y. M., Koutcher, J. A., Satagopan, J. M., Reuter, V., Carver, B. S., de Stanchina, E., Enomoto, K., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci60720 · Cited by 88
Self-citation
Antitumor activity of HER-2 inhibitors
Rabindran, S. K. (2004) · Cancer Letters · doi:10.1016/j.canlet.2004.11.015 · Cited by 87
HER2-family signalling mechanisms, clinical implications and targeting in breast cancer
Elster, N., Collins, D. M., Toomey, S., Crown, J. P., Eustace, A. J., & Hennessy, B. T. (2014) · Breast Cancer Research and Treatment · doi:10.1007/s10549-014-3250-x · Cited by 87
Tyrosine kinase inhibitors
Arteaga, C. L., & Baselga, J. M. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.05.028 · Cited by 87
A new therapeutic antibody masks ErbB2 to its partners
Badache, A., & Hynes, N. E. (2004) · Cancer Cell · doi:10.1016/s1535-6108(04)00088-1 · Cited by 87
ErbB family receptor inhibitors as therapeutic agents in breast cancer: Current status and future clinical perspective
Saxena, R., & Dwivedi, A. (2010) · Medicinal Research Reviews · doi:10.1002/med.20209 · Cited by 88
Structure and Function of the Epidermal Growth Factor (EGF⧸ErbB) Family of Receptors
Leahy, D. J. (2004) · Advances in protein chemistry · doi:10.1016/s0065-3233(04)68001-6 · Cited by 86
Phase IIa Trial of Trastuzumab Emtansine With Pertuzumab for Patients With Human Epidermal Growth Factor Receptor 2–Positive, Locally Advanced, or Metastatic Breast Cancer
Miller, K. D., Dieras, V. C., Harbeck, N., André, F., Mahtani, R. L., Gianni, L., Albain, K. S., Crivellari, D., Fang, L., Michelson, G. C., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.52.6590 · Cited by 85
Reduced Dose and Intermittent Treatment with Lapatinib and Trastuzumab for Potent Blockade of the HER Pathway in HER2/ neu -Overexpressing Breast Tumor Xenografts
Rimawi, M. F., Wiechmann, L., Wang, Y.-C., Huang, C., Migliaccio, I., Wu, M.-F., Gutiérrez, C., Hilsenbeck, S. G., Arpino, G., Massarweh, S. A., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1905 · Cited by 85
Structural basis of a novel heterodimeric Fc for bispecific antibody production
Wei, H., Cai, H., Jin, Y., Wang, P., Zhang, Q., Lin, Y., Wang, W., Cheng, J., Zeng, N., Xu, T., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.17558 · Cited by 81
A system for quantifying dynamic protein interactions defines a role for Herceptin in modulating ErbB2 interactions
Wehrman, T. S., Raab, W. J., Casipit, C. L., Doyonnas, R., Pomerantz, J. H., & Blau, H. M. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0605218103 · Cited by 84
Understanding the HER family in breast cancer: interaction with ligands, dimerization and treatments
Barros, F., Powe, D. G., Ellis, I. O., & Green, A. R. (2010) · Histopathology · doi:10.1111/j.1365-2559.2010.03494.x · Cited by 83
Metastatic Extramammary Paget’s Disease: Pathogenesis and Novel Therapeutic Approach
Fukuda, K., & Funakoshi, T. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00038 · Cited by 87

Authors: Agus, D. B., Akita, R. W., Fox, W. D., Lewis, G. D., Higgins, B., Pisacane, P. I., Lofgren, J. A., Tindell, C., Evans, D. P., Maiese, K., Scher, H. I., & Sliwkowski, M. X.
Affiliations: Cedars-Sinai Medical Center (US)
Genentech (US)
Memorial Sloan Kettering Cancer Center (US)
Corresponding author: Sliwkowski, Mark X
ORCID: Agus, David B
Scher, Howard I
Sliwkowski, Mark X
Venue: Cancer Cell
Publisher: Elsevier BV
Published: 2002-08
Volume: 2
Issue: 2
Pages: 127-137
ISSN: 1535-6108 (ISSN-L)
DOI: 10.1016/s1535-6108(02)00097-1
OpenAlex: W2014457594
Cited by: 873
References: 83
Citations by year: 2026: 2 · 2025: 10 · 2024: 21 · 2023: 38 · 2022: 21 · 2021: 21 · 2020: 28 · 2019: 29 · 2018: 27 · 2017: 24 · 2016: 38 · 2015: 48 · 2014: 69 · 2013: 59 · 2012: 51
FWCI: 16.85
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/open-access/userlicense/1.0/ (vor, 4003 d)
Locations: Cancer Cell (publishedVersion)
PubMed (publishedVersion)
Funders: PepsiCo
Topics: Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
Keywords: ERBB2, HER2, HER3, neuregulin-1, ErbB receptor family, breast cancer, prostate cancer, tumor growth inhibition, tyrosine kinase inhibitors
MeSH terms: Androgens, Animals, Antibodies, Monoclonal, Antineoplastic Agents, Breast Neoplasms, Cell Division, Female, Humans, Ligands, Male, Neoplasm Transplantation, Prostatic Neoplasms, Protein Binding, RNA, Messenger, Time Factors, Transplantation, Heterologous, Tumor Cells, Cultured, Signal Transduction, Gene Expression Regulation, Neoplastic, Erb-b2 Receptor Tyrosine Kinases, Neuregulin-1, Receptor, ErbB-3, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks